calcium acetate has been researched along with Chronic Kidney Diseases in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Godugu, K; Mason, DL; Mousa, SA; Nnani, D | 1 |
| Berner, T; Dieguez, G; Ferro, C; Kovesdy, CP; Metz, S; Moore, J; Szabo, E | 1 |
| Block, GA; Chertow, GM; Chonchol, M; de Boer, IH; Ginsberg, C; Hoofnagle, A; Kestenbaum, B; Zelnick, LR | 1 |
| Chatterley, T; Dorgan, M; Fitchett, D; Jamal, SA; Lok, CE; Mendelssohn, DC; Raggi, P; Tsuyuki, RT; Vandermeer, B | 1 |
| Allison, SJ | 1 |
| Cancela, AL; Canziani, ME; Carvalho, AB; Cuppari, L; de Oliveira, RB; dos Reis, LM; Graciolli, FG; Jorgetti, V; Moysés, RM | 1 |
| Bennett-Jones, D; Dasgupta, I; McVeigh, G; Shroff, R | 1 |
| Guo, X; Liu, X; Liu, Z; Ma, W; Su, G; Wu, Y; Xu, Y; Yang, Q; Zhang, L; Zou, C | 1 |
| Cho, JH; Choi, JY; Jang, HM; Jin, DC; Jung, HY; Kim, CD; Kim, YL; Park, SH; Yang, CW | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Diaz-Buxo, JA; Greenberg, J; Ho, CH; Kessler, P; Moustafa, M; Qunibi, W; Solomon, R; Winkelmayer, WC | 1 |
| Drüeke, TB; Massy, ZA | 1 |
| Allison, MA; Asplin, J; Block, GA; Chertow, GM; Hoofnagle, AN; Kestenbaum, B; Ketteler, M; Kooienga, L; Mannstadt, M; Persky, MS; Smits, G; Spiegel, DM; Thadhani, R; Wheeler, DC; Wolf, M | 1 |
| Evenepoel, P; Meijers, B | 1 |
| Bernard, LM; Dunn, ES; Grima, DT; Mendelssohn, DC | 1 |
| Acikel, C; Axelsson, J; Caglar, K; Cakir, E; Carrero, JJ; Eyileten, T; Lindholm, B; Oguz, Y; Saglam, M; Stenvinkel, P; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
4 review(s) available for calcium acetate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
Topics: Acetates; Aged; Calcium Carbonate; Calcium Compounds; Cause of Death; Chelating Agents; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chelation Therapy; Diet Therapy; Evidence-Based Medicine; Humans; Hyperphosphatemia; Nephrology; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; United States | 2013 |
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
Topics: Acetates; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Bread; Calcium; Calcium Compounds; Calcium Phosphates; Calcium, Dietary; Dietary Proteins; Fibroblast Growth Factor-23; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phosphorus; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic | 2015 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
5 trial(s) available for calcium acetate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Topics: Acetates; Aged; Calcium Compounds; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2020 |
Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
Topics: Acetates; Adaptor Proteins, Signal Transducing; Adiponectin; beta Catenin; Biomarkers; Bone Density; Bone Diseases; Bone Morphogenetic Proteins; Calcium Compounds; Chelating Agents; Energy Metabolism; Female; Fibroblast Growth Factor-23; Genetic Markers; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Male; Middle Aged; Polyamines; Renal Insufficiency, Chronic; Serotonin; Sevelamer; Wnt Proteins | 2013 |
A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease.
Topics: Acetates; Calcium; Calcium Compounds; Chelating Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Male; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2011 |
Effects of phosphate binders in moderate CKD.
Topics: Acetates; Aged; Aged, 80 and over; Bone Density; Calcium Compounds; Chelating Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2012 |
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.
Topics: Acetates; Adult; alpha-2-HS-Glycoprotein; Blood Proteins; C-Reactive Protein; Calcinosis; Calcium; Calcium Compounds; Chelating Agents; Endothelium, Vascular; Homeostasis; Humans; Middle Aged; Phosphates; Polyamines; Prospective Studies; Renal Insufficiency, Chronic; Sevelamer; Treatment Outcome; Vascular Diseases; Vasodilation | 2008 |
7 other study(ies) available for calcium acetate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease.
Topics: Acetates; Calcium; Calcium Compounds; Chelating Agents; Humans; Inflammation; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2022 |
Real-World Phosphate Binder Use among Dialysis-Dependent Patients with CKD.
Topics: Aged; Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Medicare; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; United States | 2023 |
Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders: effect on mortality in patients with CKD.
Topics: Acetates; Calcium Compounds; Chelating Agents; Global Health; Humans; Phosphates; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate | 2013 |
A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients.
Topics: Acetates; Adult; Aged; Asian People; Calcium Compounds; Chelating Agents; Cost-Benefit Analysis; Female; Hospitalization; Humans; Male; Markov Chains; Middle Aged; National Health Programs; Prospective Studies; Quality-Adjusted Life Years; Regression Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Republic of Korea; Sevelamer | 2018 |
Phosphate binders in CKD: bad news or good news?
Topics: Acetates; Calcium Compounds; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
Topics: Acetates; Blood Vessels; Calcinosis; Calcium Compounds; Chelating Agents; Disease Progression; Humans; Hyperphosphatemia; Lanthanum; Phosphate-Binding Proteins; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis.
Topics: Acetates; Calcium Compounds; Chelating Agents; Confidence Intervals; Female; Hospitalization; Humans; Hyperphosphatemia; Male; Markov Chains; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer | 2013 |